Locally advanced prostate cancer: Definition, prognosis and treatment;Cancer de la prostate localisé à haut risque: Définition, pronostic et traitement

Bulletin du Cancer

Volumn 94, Issue 6 SUPPL., 2007, Pages

  Plantade, Anne ^a   Massard, Christophe ^a   De Crevoisier, Renaud ^a   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; High risk prostate cancer; Radiation

Indexed keywords

BICALUTAMIDE; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADVANCED CANCER; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; GLEASON SCORE; HORMONAL THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW;

ANDROGEN ANTAGONISTS; ANILIDES; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NITRILES; PELVIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; TOSYL COMPOUNDS;

EID: 34547769342     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0367     Document Type: Review

References (67)

1. Hill C, Doyon F. The frequency of cancer in France in year 2002, and rrends since 1968. Bull Cancer 2006 ; 9 : 7-11.
2. Brenner H, Arndr V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era : population-based estimates for rhe year 2000 by period analysis. J Clin Oncol 2005 ; 23 : 441-7.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or inrerstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 ; 280 : 969-74.
4. Pisrers LL. The challenge of locally advanced prostate cancer. Semin Oncol 1999 ; 26 : 202-16.
5. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperarive nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998 ; 90 : 766-71.
6. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 ; 277 : 1445-51.
7. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen : the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995 ; 154 : 1090-5.
8. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988 : 15-8.
9. Beahrs OH, Henson D, Hutter RVP. American Joint Comittee on Cancer : Manual for staging cancer. 4th ed. Philadelphia, Pa : JB Lippincott, 1992.
10. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database : a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1996; 48: 773-7.
11. Sun L, Gancarczyk KJ, Paquette EL, et al. Introduction to Deparrment of Defense Center for Prostate Disease Research multicenter national prostate cancer database, and analysis if changes in the PSA-era. Urol Oncol 2001 ; 6 : 203-9.
12. Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer : incidence and predictors of outcome. Cancer 2006 ; 107 : 439-50.
13. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer : comparison of the extended and modified techniques. J Urol 1997 ; 158: 1891-4.
14. Heidenteich A, Varga Z, Von Knobloch R. Extended pelvic lymphade-nectomy in patients undergoing radical prostatectomy : high incidence of lymph node metastasis. J Urol 2002 ; 167 : 1681-6.
15. Bader P, Burkhard FC, Markwalder R, et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002 ; 168 : 514-518 [discussion 518].
16. Goyal LK, Fired DB, Shelton J, et al. Abstract 173. ASCO prostate. 2006.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 ; 293 : 2095-101.
18. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006 ; 68 : 121-5.
19. Ravery V, Chastang C, Toublanc M, et al. Percentage of cancer on biopsy cores accurately predicrs extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol 2000 ; 37 : 449-55.
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000 ; 18 : 1164-72.
21. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351 : 125-35.
22. Eggener SE, Roehl KA, Catalona WJ. Predicrors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol 2005 ; 174 : 500-4.
23. Roberts T, Roach M. The evolving role of pelvic radiation therapy. Semin Radiat Oncol 2003 ; 13 : 109-20.
24. Pommier P, Perol D, Lagrange J, et al. Does pelvis and prostate radiotherapy compared to prostate radiotherapy alone improve survival in patients with non metastatic prostate carcinoma? Preliminary results of the prospective randomized Getug01 trial. Int J Radiat Oncol Biol Phys 2005 ; 63 : 33.
25. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer : the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared wirh conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995 ; 32 : 3-12.
26. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiarion dose response : results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002 ; 53 : 1097-105.
27. Lebesque JV, Bruce AM, Kroes AP, et al. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995 ; 33 : 1109-19.
28. De Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005 ; 62 : 965-73.
29. Ohoti M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994 ; 152 : 1843-9.
30. Van den Ouden D, Davidson PJ, Hop W, et al. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994 ; 151 : 646-51.
31. Van Poppel H, Goethuys H, Callewaert P, et al. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000 ; 38 : 372-9.
32. Lerner SE, Blute ML, Bergstralh EJ, et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996 ; 156 : 137-43.
33. Van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998 ; 160 : 1392-7.
34. Inman BA, et al. Abstract 179. ASCO Prostate. 2006.
35. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy : a randomised controlled trial (EORTC trial 22911). Lancet 2005 ; 366 : 572-8.
36. Wiegel, et al. Abstract 4513. ASCO. 2005.
37. Swanson GP, Thompson IM, Tangen C, et al. Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancel (SWOG 8794). Int J Radiat Oncol Biol Phys 2005 ; 63 :S1.
38. Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer. Justification by long-term follow-up. Urol Clin North Am 1990 ; 17 : 787-802.
39. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancet (an EORTC study): a phase III randomised trial. Lancet 2002 ; 360 : 103-6.
40. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating rhe potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001 ; 49 : 937-46.
41. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer : a randomized controlled trial. JAMA 2004 ; 292 : 821-7.
42. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate : the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003 ; 21 ; 3972-8.
43. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 ; 7 : 472-9.
44. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate : updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005 ; 23 : 800-7.
45. Leod M, et al. Abstract 181, ASCO Prostate. 2006.
46. Sternberg CN. Apples and oranges. Re : 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU Int 2006 ; 97 : 435-8.
47. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351 : 1513-20.
48. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351 : 1502-12.
49. Beer TM, Garzotto M, Lowe BA, et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004 ; 10 : 1306-11.
50. Gleave M, Chi K, Goldenberg L, et al. Multicentre phase 2 trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer. J Clin Oncol 2004 ; 22 : 45 IS (suppl; abstr 4635).
51. Schmidt JD, Gibbons RP, Murphy GP, et al. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996; 29: 425-33.
52. Khil MS, Kim JH, Bricker LJ, et al. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 1997 ; 3 : 289-96.
53. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer : results of a phase I/II study. J Urol 2004; 171 : 709-13.
54. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy : feasibility and preliminary results. J Clin Oncol 2000 ; 18 : 1050-7.
55. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004 ; 63 : 1138-42.
56. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer : a preliminary report. Semin Oncol 2001 ; 28 (4 Suppl 15): 40-4.
57. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005 ; 11 : 5233-40.
58. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003 ; 61 : 774-80.
59. Ko Y, Dewolf W, Olumi A, et al. Neoadjuvant chemohormonal therapy followed by radical prostatectomy for high-risk prostate cancer. Proc Am Soc Clin Oncol 21 : 162b [abstr 2465].
60. Clark PE, Peereboom DM, Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001 ; 57 : 281-5.
61. Wang J, Halford S, Rigg A, et al. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 2000 ; 86 : 675-80.
62. Ryan CJ, Zelefsky MJ, Heller G, et al. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology 2004 ; 64 : 90-4.
63. Fizazi K, et al. ASCO. 2006.
64. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001 ; 50 : 1243-52.
65. Zelefsky MJ. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Urol Oncol 2006 ; 24 : 376-7.
66. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neo-adjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004 ; 60 : 15-23.
67. Roach M, Desilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic vs prostate-only radiotherapy and neo-adjuvant vs adjuvant combined androgen suppression : Radiation Therapy Oncology Group 94-13. J Clin Oncol 2003 : 211904-11.